Evidence from ASCO 2025–2026
China’s Oncology Paradigm Shift: From Proof-of-Concept to FDA Registration Pathway —
EXECUTIVE SUMMARY
ASCO 2026 provides definitive evidence that China has completed its transition from a proof-of-concept and enrollment-speed geography to a validated FDA registration pathway for oncology therapeutics.
- The ivonescimab HARMONi-6 plenary presentation delivering a 34% reduction in death risk (HR=0.66; median OS 27.9 vs. 23.7 months; two-year survival 64.7% vs. 48.6%) with simultaneous Lancet publication and FDA BLA acceptance.
- Represents the first China-originated study to achieve both ASCO plenary status and U.S. regulatory submission acceptance. This milestone, occurring just four years after sintilimab’s 14-1 ODAC rejection,
- Establishes a replicable framework: first-in-class mechanisms addressing genuine unmet need, proactive FDA engagement, and multiregional design where appropriate.
The paradigm shift extends well beyond a single molecule. At ASCO 2026, izalontamab brengitecan demonstrated OS hazard ratios of 0.60 in TNBC and 0.64 in esophageal SCC, sacituzumab tirumotecan achieved an OS HR of 0.55 in first-line NSCLC, and IBI363 reported an 86.4% ORR in early proof-of-concept, magnitudes of benefit comparable to daraxonrasib’s practice-changing HR of 0.40 in pancreatic cancer.
- These programs are underpinned by licensing partnerships totaling approximately $15 billion in potential value (SystImmune- BMS $8.4B, Akeso→Summit $5B, Kelun-Merck $1.4B+), confirming multinational pharma’s willingness to invest at registration-pathway valuations for China-originated assets.
For CRO strategy, this convergence of regulatory precedent, clinical validation, and commercial deal flow necessitates upgrading China from a phase III to speed-and-PoC must for an an integrated registration pathway offering.
- The Australia+China bundled Phase I/II model, leveraging Australia’s CTN pathway for Western-patient PK/safety data alongside China’s enrollment velocity, positions CROs to serve the full development arc from first-in-human through BLA submission, capturing value at each stage of the China-to-global commercialization journey.
Introduction
The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting marked a watershed moment in global oncology drug development. For the first time, a China-originated, China-conducted Phase III study, the HARMONi-6 trial of ivonescimab — was selected for plenary presentation and simultaneously accepted by the U.S. Food and Drug Administration as the basis for a Biologics License Application. This milestone, combined with an unprecedented wave of China-originated bispecific antibodies and antibody-drug conjugates (ADCs) reporting positive Phase III data at the same meeting, signals a fundamental transformation in China’s role within the global oncology development ecosystem.
Historically, China’s value proposition for multinational clinical development has centered on two pillars: rapid proof-of-concept (PoC) generation and enrollment speed. The regulatory landscape was characterized by the 2022 sintilimab ODAC rejection, where a 14-1 vote concluded that China-only data could not support U.S. approval. Four years later, the ivonescimab BLA acceptance demonstrates that China-originated programs can now achieve FDA registration — provided they meet specific design, mechanistic, and engagement criteria. This evolution, combined with licensing deals totaling approximately $22 billion in potential value across three landmark partnerships , compels a strategic reassessment of China’s position in the global development pathway.
This evidence supports Emerald Clinical’s China Edge from “Growth PoC & Speed” to “Growth PoC, Speed & Registration Pathway,” analyzing clinical data, regulatory precedent, and strategic implications for CRO positioning in the China-to-global development era.
To read the full article please fill out the form below.